C. Haiyan, W. Meilin, and Z. Zhendong, Bladder cancer epidemiology and genetic susceptibility, J Biomed Res, vol.27, issue.3, pp.170-178, 2013.

J. Burch, T. Rohan, and G. Howe, Risk of bladder cancer by source and type of tobacco exposure: A case-control study, International Journal of Cancer, vol.40, issue.4, pp.622-630, 1989.
DOI : 10.1002/ijc.2910440411

J. Irani, Prise en charge des tumeurs de vessie n???infiltrant pas le muscle (TVNIM), Progr??s en Urologie, vol.19, issue.4, pp.248-253, 2009.
DOI : 10.1016/j.purol.2008.10.025

C. Pfister, M. Roupret, and H. Wallerand, Oncology Commitee of the French Association of Urology) Recommendations onco-urology 2010 : Urothelial tumors, Prog Urol, vol.4, pp.255-74, 2010.

Y. Miyoshi, J. Matsuzaki, and T. Miura, Evaluation of usefulness of urinary nuclear matrix protein 22 (NMP22) in the detection of urothelial transitional cell carcinoma, Hinyokika Kiyo, vol.47, pp.379-83, 2001.

M. Paoluzzi, M. Cuttano, and P. Mugnaini, Urinary dosage of nuclear matrix protein 22 (NMP22) like biologic marker of transitional cell carcinoma (TCC): a study on patients with hematuria, Arch Ital Urol Androl, vol.71, pp.13-18, 1999.

M. Sarosdy, P. Kahn, and M. Ziffer, Evaluation of a multi-target fluorescent in situ hybridization (FISH) assay in the initial diagnosis of bladder cancer in patients with hematuria, J Urol, vol.171, issue.4, p.66, 2004.

C. Spruck, . Rd, P. Ohneseit, and M. Gonzalez-zulueta, Two molecular pathways to transitional cell carcinoma of the bladder, Cancer Res, vol.54, issue.3, pp.784-792, 19941.

A. Bakkar, H. Wallerand, and F. Radvanyi, FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder, Cancer research, vol.63, issue.23, pp.8108-8120, 2003.

B. Van-rhijn, T. Van-der-kwast, and A. Vis, FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma, Cancer Research, vol.64, issue.6, p.1911, 2004.
DOI : 10.1158/0008-5472.CAN-03-2421

J. Flaman, T. Frebourg, and V. Moreau, A simple p53 functional assay for screening cell lines, blood, and tumors., Proceedings of the National Academy of Sciences, vol.92, issue.9, pp.3963-3970, 199525.
DOI : 10.1073/pnas.92.9.3963

J. Van-oers, I. Lurkin, and A. Van-exsel, A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine, Clinical Cancer Research, vol.11, issue.21, pp.7743-7751, 2005.
DOI : 10.1158/1078-0432.CCR-05-1045

X. Wu, M. Ros, and J. Gu, Epidemiology and genetic susceptibility to bladder cancer, BJU International, vol.16, issue.Suppl., pp.1207-1222, 2008.
DOI : 10.1111/j.1464-410X.2008.07961.x

D. Chopin and B. Gattegno, Epidemiologie descriptive des tumeurs superficielles de la vessie, Prog Urol, vol.11, pp.953-960, 2001.

A. Belot, P. Grosclaude, and N. Bossard, Cancer incidence and mortality in France over the period 1980???2005, Revue d'??pid??miologie et de Sant?? Publique, vol.56, issue.3, pp.159-75, 2008.
DOI : 10.1016/j.respe.2008.03.117

URL : https://hal.archives-ouvertes.fr/hal-00538673

J. Irani, Epidemiologie du cancer de vessie, Prog Urol, vol.13, pp.1207-1208, 2003.

X. Rebillard, P. Grosclaude, and T. Lebret, Projection de l???incidence et de la mortalit?? par cancer urologique en France en 2010, Progr??s en Urologie, vol.20, pp.211-214, 2010.
DOI : 10.1016/S1166-7087(10)70041-5

M. Zeegers, F. Tan, and E. Dorant, The impact of characteristics of cigarette smoking on urinary tract cancer risk, Cancer, vol.29, issue.3, pp.630-639, 2000.
DOI : 10.1002/1097-0142(20000801)89:3<630::AID-CNCR19>3.0.CO;2-Q

P. Brennan, O. Bogillot, and E. Greiser, Cigarette smoking and bladder cancer in men: A pooled analysis of 11 case-control studies, International Journal of Cancer, vol.61, issue.2, pp.289-94, 2000.
DOI : 10.1002/(SICI)1097-0215(20000415)86:2<289::AID-IJC21>3.0.CO;2-M

P. Aveyard, P. Adab, and K. Cheng, Does smoking status influence the prognosis of bladder cancer? A systematic review, BJU International, vol.84, issue.3, pp.228-239, 2002.
DOI : 10.1046/j.1464-410X.2002.02880.x

L. Guy, Les tumeurs de vessie d'origine professionnelle, Progrès FMC, vol.174, pp.18-24, 2007.

E. Imbernon, Estimation du nombre de cas de certains cancers attribuables à des facteurs professionnels en France : 15-16. Département santé travail-Institut de veille sanitaire, p.28, 2003.

F. Donato, P. Boffeta, and R. Fazioli, Bladder cancer, tobacco smoking, coffee and alcohol drinking in Brescia, northern Italy, European Journal of Epidemiology, vol.13, issue.7, pp.795-800, 1997.
DOI : 10.1023/A:1007453322899

C. Pelucchi, E. Negri, and S. Franceschi, Alcohol drinking and bladder cancer, Journal of Clinical Epidemiology, vol.55, issue.7, pp.637-678, 2002.
DOI : 10.1016/S0895-4356(02)00397-9

URL : https://hal.archives-ouvertes.fr/hal-01262903

M. Zeegers, A. Volovics, and E. Dorant, Alcohol Consumption and Bladder Cancer Risk: Results from the Netherlands Cohort Study, American Journal of Epidemiology, vol.153, issue.1, pp.38-41, 2001.
DOI : 10.1093/aje/153.1.38

J. Widran, R. Sanchez, and J. Gruhn, Squamous metaplasia of the bladder: a study of 450 patients

T. Laskowski and F. Scott, Cutaneous vesicostomy as means of urinary diversion: 3 years of experience, J Urol, vol.94, pp.549-554, 1965.

J. Kaufman, B. Fam, and S. Jacobs, Bladder cancer and squamous metaplasia in spinal cord injury patients, J Urol, vol.118, pp.967-971, 1997.

M. Sheaff and B. Jenkins, Squamous cell carcinoma of the bladder following radiotherapy for transitional cell carcinoma, British Journal of Urology, vol.65, issue.1, pp.131-132, 1994.
DOI : 10.1111/j.1464-410X.1994.tb16569.x

M. El-bolkainy, N. Mokhtar, and M. Ghoneim, The impact of schistosomiasis on the pathology of bladder carcinoma, Cancer, vol.118, issue.12, pp.2643-2648, 1981.
DOI : 10.1002/1097-0142(19811215)48:12<2643::AID-CNCR2820481216>3.0.CO;2-C

K. Stamatiou, I. Papadoliopoulos, and S. Dahanis, The accuracy of ultrasonography in the diagnosis of superficial bladder tumors in patients presenting with hematuria, Annals of Saudi Medicine, vol.29, issue.2, pp.134-137, 2009.
DOI : 10.4103/0256-4947.51802

M. Rouprêt, T. Seisen, and E. Compérat, Prognostic Interest in Discriminating Muscularis Mucosa Invasion (T1a vs T1b) in Nonmuscle Invasive Bladder Carcinoma: French National Multicenter Study with Central Pathology Review, The Journal of Urology, vol.189, issue.6, pp.2069-76
DOI : 10.1016/j.juro.2012.11.120

Y. Pointreau, S. Klotz, and F. Denis, Cancer de la Vessie, Cancer/Radioth??rapie, vol.14, pp.189-197, 2010.
DOI : 10.1016/S1278-3218(10)70023-8

M. May, S. Brookman-amissah, and J. Roigas, Prognostic Accuracy of Individual Uropathologists in Non Invasive Urinary Bladder Carcinoma : A Multicentre Study Comparing the, World Health Organisation Classifications. Eur Urol, vol.10, p.1016, 1973.

A. Karl, P. Caroll, and J. Gshwend, The Impact of Lymphadenectomy and Lymph Node Metastasis on the Outcomes of Radical Cystectomy for Bladder Cancer, European Urology, vol.55, issue.4, pp.826-861, 2009.
DOI : 10.1016/j.eururo.2009.01.004

R. Sylvester, A. Van-der-meijden, and W. Oosterlinck, Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials, European Urology, vol.49, issue.3, pp.466-77, 2006.
DOI : 10.1016/j.eururo.2005.12.031

M. Huncharek, R. Mcgarry, and B. Kupelnick, Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis

D. Lamm, B. Blumenstein, and J. Crissman, MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY, The Journal of Urology, vol.163, issue.4, pp.1124-1133, 2000.
DOI : 10.1016/S0022-5347(05)67707-5

T. Karmouni, K. Bensalah, and A. A. , Place de l'antibioprophylaxie lors d'une cystoscopie en ambulatoire, Prog Urol, vol.11, issue.11, pp.1239-1241, 2001.

Y. Almallah, C. Rennie, and J. Stone, Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation, Urology, vol.56, issue.1, pp.37-46, 2000.
DOI : 10.1016/S0090-4295(00)00555-0

J. Witjes, R. Palou, J. Jacqmin, and D. , Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non???Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations, European Urology, vol.57, issue.4, pp.607-614, 2010.
DOI : 10.1016/j.eururo.2010.01.025

D. Jocham, F. Witjes, and S. Wagner, IMPROVED DETECTION AND TREATMENT OF BLADDER CANCER USING HEXAMINOLEVULINATE IMAGING: A PROSPECTIVE, PHASE III MULTICENTER STUDY, The Journal of Urology, vol.174, issue.3, pp.862-866, 2005.
DOI : 10.1097/01.ju.0000169257.19841.2a

E. J. Meuleman and K. P. Delaere, Diagnostic Efficacy of the Combination of Urine Cytology, Urine Analysis and History in the Follow-up of Bladder Carcinoma, British Journal of Urology, vol.55, issue.Suppl., pp.150-153, 1988.
DOI : 10.1111/j.1464-410X.1988.tb04296.x

B. Fontanière, D. Ranchère-vince, and J. Landry, Critères de qualité de la cytologie urinaire pour le diagnostic tumoral, Prog Urol, vol.11, pp.867-875, 2011.

H. B. Grossman, New methods for detection of bladder cancer, Semin Urol Oncol, vol.16, pp.17-22, 1998.

V. Kannan and S. Bvose, Low grade transitional cell carcinoma and instrument artefact. A challenge in urinary cytology, Acta Cytol, vol.37, pp.899-902, 1993.

P. Quek, C. Chin, and P. Lim, The role of BTA stat in clinical practice, Ann Acad Med Singapore, vol.31, pp.212-228, 2002.

J. Irani, Les nouveaux tests diagnostiques des tumeurs urothéliales de vessie, Prog Urol, vol.8, pp.481-486, 1998.

D. S. Stampfer, G. A. Carpinito, and J. Rodriguez-villanueva, EVALUATION OF NMP22 IN THE DETECTION OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER, The Journal of Urology, vol.159, issue.2, pp.394-398, 1998.
DOI : 10.1016/S0022-5347(01)63930-2

J. Campos-fernandes, F. Descotes, and A. J. , Int??r??t des marqueurs urinaires dans le diagnostic et le suivi des tumeurs uroth??liales de vessie, Progr??s en Urologie, vol.17, issue.1, pp.23-24, 2007.
DOI : 10.1016/S1166-7087(07)92221-6

R. Berezney, The nuclear matrix: A heuristic model for investigating genomic organization and function in the cell nucleus, Journal of Cellular Biochemistry, vol.7, issue.2, pp.109-123, 1991.
DOI : 10.1002/jcb.240470204

S. F. Shariat, C. Zippe, and G. Ludecke, NOMOGRAMS INCLUDING NUCLEAR MATRIX PROTEIN 22 FOR PREDICTION OF DISEASE RECURRENCE AND PROGRESSION IN PATIENTS WITH Ta, T1 OR CIS TRANSITIONAL CELL CARCINOMA OF THE BLADDER, The Journal of Urology, vol.173, issue.5, pp.1518-1525, 2005.
DOI : 10.1097/01.ju.0000154696.48217.75

B. Johnston, A. Moraies, and L. Emerson, RAPID PROTECTION OF BLADDER CANCER: A COMPARATIVE STUDY OF POINT OF CARE TESTS, The Journal of Urology, vol.158, issue.6, pp.2098-2103, 1997.
DOI : 10.1016/S0022-5347(01)68166-7

F. Saint, H. Quintens, and M. Roupret, Actualit??s urologiques concernant les tests diagnostiques utilis??s pour les tumeurs de vessie??: le NMP22, Progr??s en Urologie, vol.21, issue.4, pp.245-249, 2011.
DOI : 10.1016/j.purol.2010.09.027

N. Gupta, N. Sharma, and R. Kumar, Nuclear Matrix Protein 22 as Adjunct to Urine Cytology and Cystoscopy in Follow-up of Superficial TCC of Urinary Bladder, Urology, vol.73, issue.3, pp.592-596, 2009.
DOI : 10.1016/j.urology.2008.04.051

L. Budman, W. Kassouf, and J. Steinberg, Biomarkers for detection and surveillance of bladder cancer, Canadian Urological Association Journal, vol.2, issue.3, pp.212-221, 2008.
DOI : 10.5489/cuaj.600

G. Banos, J. L. , M. Garcia, B. De-diego-rodriguez, and E. , The BTA STAT test in the follow-up for bladder cancer, Arch Esp Urol, vol.52, pp.856-861, 1999.

S. Sharma, C. Zippe, and L. Pandrangi, EXCLUSION CRITERIA ENHANCE THE SPECIFICITY AND POSITIVE PREDICTIVE VALUE OF NMP22* AND BTA STAT [dagger], The Journal of Urology, vol.162, issue.1, pp.53-60, 1999.
DOI : 10.1097/00005392-199907000-00014

M. Raitanen, P. Hellstrom, and T. Martilla, Effect of Intravesical Instillations on the Human Complement Factor H Related Protein (BTA <i>stat</i>) Test, European Urology, vol.40, issue.4, pp.422-428, 2001.
DOI : 10.1159/000049810

C. Pfister, D. Chautard, and M. Devonec, Immunocyt Test Improves the Diagnostic Accuracy of Urinary Cytology: Results of a French Multicenter Study, The Journal of Urology, vol.169, issue.3, pp.921-924, 2003.
DOI : 10.1097/01.ju.0000048983.83079.4c

M. Lodde, C. Mian, and G. Negri, Role of uCyt+ in the detection and surveillance of urothelial carcinoma, Urology, vol.61, issue.1, pp.243-247, 2003.
DOI : 10.1016/S0090-4295(02)02073-3

C. Mian, M. Lodde, and E. Comloj, The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ in the urinary bladder, Anticancer Res, vol.25, pp.3641-3645, 2005.

E. Piaton, A. Ruffion, and F. Collet, Apport de l'immunocytochimie en fluorescence (uCyt+) dans la surveillance après résection des tumeurs vésicales, Prog Urol, vol.14, pp.315-319, 2004.

J. Placer, B. Espinet, and M. Salido, Clinical Utility of a Multiprobe FISH Assay in Voided Urine Specimens for the Detection of Bladder Cancer and its Recurrences, Compared with Urinary Cytology, European Urology, vol.42, issue.6, pp.547-552, 2002.
DOI : 10.1016/S0302-2838(02)00448-7

M. Sarosdy, P. Schellhamer, and G. Bokinsky, Clinical Evaluation of a Multi-target Fluorescent in Situ Hybridization Assay for Detection of Bladder Cancer, The Journal of Urology, vol.168, issue.5, pp.1950-1954, 2002.
DOI : 10.1016/S0022-5347(05)64270-X

S. Hautmann, T. M. , L. Gomez, and M. , Immunocyt and the HA-HAase Urine Tests for the Detection of Bladder Cancer: A Side-by-Side Comparison, European Urology, vol.46, issue.4, pp.466-71, 2004.
DOI : 10.1016/j.eururo.2004.06.006

B. Little, A. Hugues, and M. Young, Use of polymerase chain reaction analysis of urinary DNA to detect bladder carcinoma, Urologic Oncology: Seminars and Original Investigations, vol.23, issue.2, pp.102-107, 2005.
DOI : 10.1016/j.urolonc.2004.10.009

L. Mao, M. Schoenberg, and M. Scicchitano, Molecular Detection of Primary Bladder Cancer by Microsatellite Analysis, Science, vol.271, issue.5249, pp.659-662, 1996.
DOI : 10.1126/science.271.5249.659

S. Mourah, O. Cussenot, and V. Vimont, Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder, International Journal of Cancer, vol.2, issue.6, pp.629-633, 1998.
DOI : 10.1002/(SICI)1097-0215(19981218)79:6<629::AID-IJC13>3.0.CO;2-1

N. Smith, J. Rubenstein, and S. Eggener, The p53 Tumor Suppressor Gene and Nuclear Protein: Basic Science Review and Relevance in the Management of Bladder Cancer, The Journal of Urology, vol.169, issue.4, pp.1219-1247, 2003.
DOI : 10.1097/01.ju.0000056085.58221.80

H. Hermeking, C. Lengauer, and K. Polyak, 14-3-3?? Is a p53-Regulated Inhibitor of G2/M Progression, Molecular Cell, vol.1, issue.1, pp.3-11, 1998.
DOI : 10.1016/S1097-2765(00)80002-7

A. Braithwaite, J. Royds, and P. Jackson, The p53 story: layers of complexity, Carcinogenesis, vol.26, issue.7, pp.1161-1169, 2005.
DOI : 10.1093/carcin/bgi091

J. Amaral, J. Xavier, and C. Steer, The role of p53 in apoptosis, Discov Med, vol.9, issue.45, pp.145-52, 2010.

C. Billerey, D. Chopin, and M. Aubriot-lorton, Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors, The American Journal of Pathology, vol.158, issue.6, pp.1955-1959, 2001.
DOI : 10.1016/S0002-9440(10)64665-2

B. Schlichtholz, M. Presler, and M. Matuszewski, Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast, Carcinogenesis, vol.25, issue.12, pp.2319-2323, 2004.
DOI : 10.1093/carcin/bgh256

C. Pfister, J. Flaman, and C. Martin, SELECTIVE DETECTION OF INACTIVATING MUTATIONS OF THE TUMOR SUPPRESSOR GENE p53 IN BLADDER TUMORS, The Journal of Urology, vol.161, issue.6, pp.1973-1978, 1999.
DOI : 10.1016/S0022-5347(05)68866-0

K. Sibley, D. Cuthbert, and M. Knowles, Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma, Oncogene, vol.20, issue.6, pp.686-691, 2001.
DOI : 10.1038/sj.onc.1204110

K. Zieger, L. Dyrskjot, and C. Wiuf, Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors, Clinical Cancer Research, vol.11, issue.21, pp.7709-7719, 2005.
DOI : 10.1158/1078-0432.CCR-05-1130

P. Chomczynski and N. Sacchi, The single-step method of RNA isolation by acid guanidinium thiocyanate???phenol???chloroform extraction: twenty-something years on, Nature Protocols, vol.22, issue.2, pp.581-586, 2006.
DOI : 10.1006/abio.1987.9999

T. Menke and J. Warnecke, Improved Conditions for Isolation and Quantification of RNA in Urine Specimens, Annals of the New York Academy of Sciences, vol.10, issue.1, pp.185-194, 2004.
DOI : 10.1196/annals.1318.028

W. Dridi, K. Krabchi, and M. Gadji, Dominant negative activity of mutated p53 proteins, Med Sci, vol.22, issue.3, pp.301-308, 2006.

A. Lamy, F. Gobet, and M. Laurent, Molecular Profiling of Bladder Tumors Based on the Detection of FGFR3 and TP53 Mutations, The Journal of Urology, vol.176, issue.6, pp.2686-2695, 2006.
DOI : 10.1016/j.juro.2006.07.132

Y. Neuzillet, X. Paoletti, and S. Ouerhani, A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer, PLoS ONE, vol.26, issue.12, 2012.
DOI : 10.1371/journal.pone.0048993.s005

URL : https://hal.archives-ouvertes.fr/hal-01358546

J. Watanabe, H. Nishiyama, and K. Okubo, Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY, Urology, vol.63, issue.5, pp.989-93, 2004.
DOI : 10.1016/j.urology.2003.11.031

S. Eissa, S. Zohny, and A. Zekri, Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence, Medical Oncology, vol.42, issue.4
DOI : 10.1007/s12032-009-9375-9

J. Prescott, J. Montie, and T. Pugh, Clinical sensitivity ofp53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens, Cancer, vol.25, issue.11, pp.2127-2162, 2001.
DOI : 10.1002/1097-0142(20010601)91:11<2127::AID-CNCR1241>3.0.CO;2-R

B. Van-rhijn, I. Lurkin, and D. Chopin, Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine, Clin Cancer Res, vol.9, pp.257-263, 2003.

T. Zuiverloon, M. Van-der-aa, T. Van-der, and . Kwast, Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle-Invasive Bladder Cancer, Clinical Cancer Research, vol.16, issue.11, pp.3011-3018, 2010.
DOI : 10.1158/1078-0432.CCR-09-3013